|
||||||||||||||||
HUM-MOLGEN -> Events -> Meetings and Conferences | ||||||||||||||||
CHI's Second Annual HUMAN PROTEOME PROJECT | ||||||||||||||||
September 21, 2001 | ||||||||||||||||
Cambridge Healthtech Institute, Hilton San Diego Resort, San Diego, California January 9-11, 2002 Second Annual Human Proteome Project January 9-11, 2002, Hilton Resort, San Diego The reason for creating HUPO is to assist in increasing the awareness of this discipline of science across society, particularly with regard to the Human Proteome Project and to engender a broader understanding of the importance of proteomics and the opportunities it offers in the diagnosis, prognosis and therapy of disease. As a global body it will also have the objective of fostering international cooperation across the proteomics community and of promoting scientific research in an on-going manner around the world. In addition to the scientific fraternity, governmental and financial constituencies will be a focus of HUPO. Both these communities will be important participants in ensuring that the substantial benefits that will result from proteomics are to be fully taken advantage of and capitalized on. The applications for proteomics are considerable: Specific proteins can be identified as highly accurate and sensitive markers for disease at a very early stage of onset, thus ensuring their utility in a diagnostic capacity. Proteins are important in the prognosis and in the monitoring of therapeutic treatments, as the under or over expression of proteins identified as being disease markers reduces with the improvement in a disease condition. An important potential application here is in increasing the speed and efficacy of clinical trials. A knowledge of protein expression patterns can provide insight into potential toxic side-effects during drug screening and lead optimisation. Proteins identified as being relevant in specific disease conditions could be valid targets for therapeutic agents and thus could have an important role in the development of new therapeutic treatments. One of the founder members of HUPO, Prof. Ian Humphery-Smith of the University of Utrecht and Glaucus Proteomics said: "Proteins are central to our understanding of cellular function and disease processes and without a concerted effort in proteomics the fruits of genomics will go unrealised. The necessity of proteomics cannot be avoided - over the last year alone some very significant advances clearly vindicate this view." Prof. Sam Hanash from the University of Michigan, USA adds: "In the field of cancer research, proteomics will very likely fill an unmet need for reliable markers that allow early diagnosis to be made. Also proteomics will likely provide a multitude of novel targets for chemoprevention and therapy, as we understand the role of protein modifications and protein-protein interactions in diseases." |
||||||||||||||||
Organized by: | Cambridge Healthtech Institute | |||||||||||||||
Invited Speakers: | Call for papers To submit a proposal to be considered for presentation, please send a 3-5 sentence summary with a title outlining your recent work in Proteomics. All proposals are subject to review by the advisory committee to ensure the overall quality of the conference program. email: Please contact Chris Spivey by e mail: cspivey@healthtech.com To join HUPO please visit the website: www.hupo.org |
|||||||||||||||
Deadline for Abstracts: | December 7, 2001 | |||||||||||||||
Registration: | http://www.chi-peptalk.com/reg.htm | |||||||||||||||
E-mail: | fvargus@healthtech.com | |||||||||||||||
Posted by: | Frederick Vargus | |||||||||||||||
Host: | wks253.healthtech.com | |||||||||||||||
|
||||||||||||||||
Generated by meetings and positions 5.0 by Kai Garlipp |